Abdul Mullick's Contact Details

Abdul Mullick's Company Details

Kyowa Kirin International plc.

Princeton, NJ, US • 719 Employees
Major Drugs

At Kyowa Kirin International (KKI), commitment to life is at our core. We strive to answer the unmet medical needs of patients, their families, and the medical professionals who care for them. With more than 700 people focused on this purpose, we are a rapidly growing specialty biopharmaceutical company, engaged in the development and commercialisation of innovative medicines in the therapy areas of oncology, nephrology and central nervous system (CNS) across Europe and the Middle East. KKI, headquartered in Marlow, England, and Galashiels, Scotland, is owned by Kyowa Kirin Co., Ltd (KKC), of Japan. Founded in 1949, KKC has a successful track record in Japan and has expanded globally. Our history of innovation is built on a strong legacy of scientific discovery and fostering collaborations that accelerate the delivery of innovative medicines to patients. Grounded in our expertise in antibody engineering, we continue to investigate new molecules with the potential to contribute to the future of healthcare and make a difference in the lives of patients. At KKI, it is our people who have helped make a real difference to our success. Working together, our employees excel in achieving results quickly and effectively, bringing diverse and unique viewpoints to the company to achieve our vision. Our passion and energy around our core values of commitment to life, innovation, integrity and teamwork help ensure that every day, each of us is focused on not just making medicines, but also making people smile. With our strong legacy and exciting future, KKI is looking for great people to join our team and support our commitment to life.